Literature DB >> 32221533

Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.

Paula Böttinger1, Karin Schreiber1, Elizabeth Hyjek2, Thomas Krausz2, Michael T Spiotto2, Madeline Steiner1, Christian Idel1, Heather Booras1, Gabriele Beck-Engeser1, Jessie Riederer1, Gerald Willimsky3,4,5, Steven P Wolf1,3, Theodore Karrison6, Elizabeth Jensen1, Ralph R Weichselbaum2, Yusuke Nakamura7, Poh Yin Yew8, Paul F Lambert9, Takeshi Kurita10, Kazuma Kiyotani7, Matthias Leisegang3, Hans Schreiber1.   

Abstract

Human papillomavirus (HPV) infection is necessary but insufficient for progression of epithelial cells from dysplasia to carcinoma-in situ (CIS) to invasive cancer. The combination of mutant cellular and viral oncogenes that regulate progression of cervical cancer (CC) remains unclear. Using combinations of HPV16 E6/E7 (E+), mutant Kras (mKras) (K+) and/or loss of Pten (P-/-), we generated autochthonous models of CC without exogenous estrogen, carcinogen or promoters. Furthermore, intravaginal instillation of adenoCre virus enabled focal activation of the oncogenes/inactivation of the tumor suppressor gene. In P+/+ mice, E6/E7 alone (P+/+E+K-) failed to cause premalignant changes, while mKras alone (P+/+E-K+) caused persistent mucosal abnormalities in about one-third of mice, but no cancers. To develop cancer, P+/+ mice needed both E6/E7 and mKras expression. Longitudinal endoscopies of P+/+E+K+ mice predicted carcinoma development by detection of mucosal lesions, found on an average of 23 weeks prior to death, unlike longitudinal quantitative PCRs of vaginal lavage samples from the same mice. Endoscopy revealed that individual mice differed widely in the time required for mucosal lesions to appear after adenoCre and in the time required for these lesions to progress to cancer. These cancers developed in the transition zone that extends, unlike in women, from the murine cervix to the distal vagina. The P-/-E+K+ genotype led to precipitous cancer development within a few weeks and E6/E7-independent cancer development occurred in the P-/-E-K+ genotype. In the P-/-E+K- genotype, mice only developed CIS. Thus, distinct combinations of viral and cellular oncogenes are involved in distinct steps in cervical carcinogenesis.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32221533      PMCID: PMC7896110          DOI: 10.1093/carcin/bgaa027

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  49 in total

1.  Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.

Authors:  Sanja Stevanović; Anna Pasetto; Sarah R Helman; Jared J Gartner; Todd D Prickett; Bryan Howie; Harlan S Robins; Paul F Robbins; Christopher A Klebanoff; Steven A Rosenberg; Christian S Hinrichs
Journal:  Science       Date:  2017-04-14       Impact factor: 47.728

2.  Estrogen and progesterone receptors in cervical human papillomavirus related lesions.

Authors:  J Monsonego; H Magdelenat; F Catalan; Y Coscas; L Zerat; X Sastre
Journal:  Int J Cancer       Date:  1991-06-19       Impact factor: 7.396

Review 3.  Reducing HPV-associated cancer globally.

Authors:  Douglas R Lowy; John T Schiller
Journal:  Cancer Prev Res (Phila)       Date:  2012-01

4.  The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.

Authors:  C K Mauck; M M Callahan; J Baker; K Arbogast; R Veazey; R Stock; Z Pan; C S Morrison; M Chen-Mok; D F Archer; H L Gabelnick
Journal:  Contraception       Date:  1999-07       Impact factor: 3.375

5.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

6.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

7.  Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

Authors:  I Melero; M C Singhal; P McGowan; H S Haugen; J Blake; K E Hellstrom; G Yang; C H Clegg; L Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Authors:  Frank T Wen; Ronald A Thisted; Donald A Rowley; Hans Schreiber
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

9.  DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.

Authors:  Janin Chandra; Julie L Dutton; Bo Li; Wai-Ping Woo; Yan Xu; Lynn K Tolley; Michelle Yong; James W Wells; Graham R Leggatt; Neil Finlayson; Ian H Frazer
Journal:  J Immunother       Date:  2017 Feb/Mar       Impact factor: 4.456

10.  Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer.

Authors:  Wina Verlaat; Robert W Van Leeuwen; Putri W Novianti; Ed Schuuring; Chris J L M Meijer; Ate G J Van Der Zee; Peter J F Snijders; Daniëlle A M Heideman; Renske D M Steenbergen; G Bea A Wisman
Journal:  Epigenetics       Date:  2018-08-24       Impact factor: 4.528

View more
  4 in total

Review 1.  Criteria to make animal studies more relevant to treating human cancer.

Authors:  Steven P Wolf; Frank T Wen; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2021-10-04       Impact factor: 7.486

2.  A novel lineage-tracing mouse model for studying early MmuPV1 infections.

Authors:  Vural Yilmaz; Panayiota Louca; Louiza Potamiti; Mihalis Panayiotidis; Katerina Strati
Journal:  Elife       Date:  2022-05-09       Impact factor: 8.713

Review 3.  Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.

Authors:  Samantha Zottnick; Alessa L Voß; Angelika B Riemer
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

Review 4.  Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.

Authors:  Haoru Dong; Xinhua Shu; Qiang Xu; Chen Zhu; Andreas M Kaufmann; Zhi-Ming Zheng; Andreas E Albers; Xu Qian
Journal:  Virol Sin       Date:  2021-06-21       Impact factor: 4.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.